Palatin Technologies (PTN) Operating Expenses (2010 - 2026)
Palatin Technologies' (PTN) quarterly Operating Expenses came in at $5.5 million in Q1 2026, up 14.3% on a YoY basis from $4.8 million in Q1 2025, and down 26.1% quarter-over-quarter from $7.4 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Operating Expenses (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Operating Expenses for 17 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 14.3% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (down 18.75% YoY), and the FY2025 full-year result was $17.5 million, down 35.3% from the prior year.
- Operating Expenses retreated to $5.5 million in Q1 2026 per PTN's latest filing, from $7.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $13.9 million in Q2 2022 and bottomed at $860968.0 in Q4 2023.
- Historically, Operating Expenses has averaged $7.1 million across 5 years, with a median of $7.8 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses tumbled 86.98% in 2023, then surged 203.3% in 2024.
- Over 5 years, Operating Expenses stood at $6.6 million in 2022, then sank by 86.98% to $860968.0 in 2023, then soared by 203.3% to $2.6 million in 2024, then jumped by 185.09% to $7.4 million in 2025, then decreased by 26.1% to $5.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.5 million, $7.4 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 5.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | 7.44 Mn |
| Sep 30, 2025 | 4.19 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 8.69 Mn |
| Mar 31, 2024 | 9.22 Mn |
| Dec 31, 2023 | 860,968.00 |
| Sep 30, 2023 | 8.21 Mn |
| Jun 30, 2023 | 12.58 Mn |
| Mar 31, 2023 | 8.50 Mn |
| Dec 31, 2022 | 6.61 Mn |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 13.87 Mn |
| Mar 31, 2022 | 8.04 Mn |
| Dec 31, 2021 | 8.77 Mn |
| Sep 30, 2021 | 7.38 Mn |
| Jun 30, 2021 | 13.88 Mn |